Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
Round 1
Reviewer 1 Report
The authors have made an ambitious review of current knowledge on PARP inhibitors and mPC. Such a review is a welcome contribution and the selection of relevant studies and the summaries are well done.
It is, however, difficult to comprehend what the authors mean. The text is in need of extensive language editing.
As above
Author Response
Thank you for your positive comments. no changes are required from the Reviewer.
Regarding the request of language editing, all the manuscript has been revised from a second expert in scientific paper , english native language. Now the manuscript is presented with a high level scientific english language .
Reviewer 2 Report
The authors present an up to date overview on PARPi's in prostate cancer end their potential role
One of the problems is the fact that combination therapy in this older patient population can impact Quality of Life.
The question remains if immediate combination therapy has similar outcome as successive treatment
minor editing
Author Response
We thank the Reviewer for the positive comments and we completely agree with their comments that are enclosed in Conclusion section 6.
No specific requests for changes in the manuscript.
The language has been edited by a second expert in scientific papers , english native language.